Fulvestrant: spreading the word, but not too thinly.
Wilcken
Nicholas R C
NR
NSW Breast Cancer Institute and Department of Medical Oncology, Westmead Hospital, NSW, Sydney, Australia. nicholasw@westgate.wh.usyd.edu.au
Stockler
Martin R
MR
D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D015713:Duplicate Publications as Topic; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D033181:Information Dissemination / Q000379:methods; D011643:Publishing / Q000592:standards / Q000706:statistics & numerical data*; D013223:Statistics as Topic / Q000592:standards; D016896:Treatment Outcome
D020847:Estrogen Receptor Modulators; D000077267:Fulvestrant; D004958:Estradiol